BioNTech founders to step down and helm new mRNA startup

Core Insights - BioNTech, initially focused on cancer, gained prominence during the COVID-19 pandemic by partnering with Pfizer to develop the first COVID-19 vaccine, Comirnaty, which peaked in sales at nearly $38 billion in 2022 [3][4] - Following the decline in vaccine sales as the pandemic subsided, BioNTech is refocusing on cancer treatments, investing heavily in a pipeline that includes vaccines, bispecific antibodies, and cell therapies [5] - The company is set to have 15 Phase 3 trials in cancer by the end of the year and anticipates multiple late-stage data readouts across major cancer types [6] Company Transition - Co-founders Ugur Sahin and Özlem Türeci will leave BioNTech by the end of the year to establish a new startup focused on next-generation mRNA innovations, with BioNTech granting certain rights to its mRNA technology in exchange for a minority stake [6] - BioNTech will concentrate on advancing its late-stage cancer medicine portfolio and is in the process of searching for successors to ensure a smooth transition [6] - Further details regarding the partnership with the new startup will be provided once an official deal is signed, expected to be completed by the end of the first half of the year [6]